Related Experiment Video
Updated: May 10, 2026
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
Correlation of inhibition of platelet aggregation after clopidogrel with post discharge bleeding events: assessment
Victor Serebruany1, Sunil V Rao, Matthew A Silva
1HeartDrug Research Laboratories, Johns Hopkins University Towson, 7600 Osler Drive, Towson, MD 21204, USA. heartdrug@aol.com
Insights
High inhibition of platelet aggregation (IPA) strongly correlates with minor bleeding events in patients on dual antiplatelet therapy. However, IPA does not reliably predict severe bleeding complications, highlighting a gap in current antiplatelet strategies.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Clinical Trial Analysis
Background:
- Dual antiplatelet therapy (aspirin plus clopidogrel) is standard for coronary artery disease (CAD) and ischemic stroke (IS).
- Bleeding risk is a major concern, potentially linked to cardiovascular mortality.
- The relationship between inhibition of platelet aggregation (IPA) and bleeding events needs further clarification for optimizing antiplatelet therapy.
Purpose of the Study:
- To investigate the correlation between IPA levels and bleeding events in patients with CAD and IS on chronic dual antiplatelet therapy.
- To evaluate the predictive value of IPA for minor and severe bleeding complications using established bleeding scales.
Main Methods:
- Secondary analysis of data from patients with CAD (n=246) and IS (n=117).
- Assessment of 5 μM ADP-induced IPA and bleeding events using TIMI, GUSTO, and BleedScore scales.
- Statistical analysis to determine correlations between IPA and bleeding event severity.
Main Results:
- IPA and bleeding risks were comparable between CAD and IS patient groups.
- Superficial bleeding episodes were highly prevalent (over 50%), often occurring in multiple distinct events.
- IPA >50% significantly correlated with minor bleeding (r²=0.58) but showed weak correlation with severe bleeding (r²=0.11).
Conclusions:
- Chronic dual antiplatelet therapy is associated with a high incidence of superficial bleeding, often underestimated in clinical trials.
- While IPA effectively predicts minor bleeding, its utility in predicting severe bleeding events is limited.
- Further research is needed to understand the clinical impact of frequent mild bleeding episodes and to refine antiplatelet strategies for improved safety.
Aims:
To correlate inhibition of platelet aggregation (IPA) with bleeding events assessed by TIMI, GUSTO, and BleedScore scales in a large cohort of patients with coronary artery disease (CAD) and ischaemic stroke (IS) treated with chronic low-dose aspirin plus clopidogrel. Data from recent trials and registries suggest a link between increased risk of bleeding and cardiovascular mortality. However, the potential association of bleeding risk and IPA is not established. It may play a critical role for the safety of more aggressive platelet inhibition or/and individual tailoring of antiplatelet strategies.
Methods And Results:
Secondary post hoc analyses of 5 microM ADP-induced IPA and bleeding complications assessed by TIMI, GUSTO, and BleedScore scales in a combined data set consisting of patients with documented CAD (n = 246) and previous IS (n = 117). Demographic characteristics differ substantially depending on the underlying vascular disease; however, IPA and bleeding risks were similar between CAD and IS. All three bleeding scales adequately captured serious haemorrhagic events, where the TIMI scale was the most exclusive, whereas BleedScore was the most inclusive. Over half of all patients experienced superficial event(s), most commonly occurring during two to three distinct bleeding episodes. There was no correlation between IPA and duration of antiplatelet therapy. Inhibition of platelet aggregation >50% strongly correlates with minor (r(2) = 0.58, P < 0.001; c-statistic = 0.92), but not severe (r(2) = 0.11, P = 0.038; c-statistic = 0.57), bleeding events.
Conclusion:
Chronic oral combination antiplatelet regimens are associated with a very high (56.5-60.7%) prevalence of superficial bleeding episodes, which are grossly underestimated in trials and registries. The role of such frequent mild complications for the overall benefit of antiplatelet therapy is entirely unknown, as is their effect on compliance. Although IPA is well suited for defining the risk of minor complications, prediction of more severe bleeding events may be challenging.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:22Formation of the Platelet Plug
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
01:24Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
01:27Coronary Artery Disease V: Interprofessional Care